Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 9:10:572853.
doi: 10.3389/fonc.2020.572853. eCollection 2020.

Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer

Wenxian Wang  1   2 , Zhangzhou Huang  3 , Zongyang Yu  4 , Wu Zhuang  3 , Weijun Zheng  5 , Zhijian Cai  6 , Lei Shi  7 , Xinmin Yu  1   2 , Guangyuan Lou  1   2 , Wei Hong  1   2 , Yiping Zhang  1   2 , Ming Chen  8 , Zhengbo Song  1   2
Affiliations

Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer

Wenxian Wang et al. Front Oncol. .

Abstract

Background: Lung immune prognostic index (LIPI) status was recently developed to predict responses to immune checkpoint inhibitor (ICI) treatments. However, it is unclear whether LIPI is a prognostic index for both patients treated with ICI monotherapy and patients treated with ICIs combined with chemotherapy (ICIs CC).

Methods: This retrospective study established the patterns of LIPI in Chinese patients with advanced non-small cell lung cancer. Lung immune prognostic index based on the derived neutrophil-to-lymphocyte ratio greater than 3 and lactate dehydrogenase greater than the upper limit of normal was developed to characterize good, intermediate, or poor LIPI status. Associations between LIPI status and progression-free survival (PFS) and overall survival (OS) were analyzed. Kaplan-Meier curves and Cox proportional hazards models were used to determine survival differences.

Results: Three hundred thirty patients were included in this study. Of these patients, 216 received ICI monotherapy and 114 received ICIs CC. A good LIPI status was associated with better PFS (6.1 months vs. 2.3 months vs. 2.1 months, P = 0.023) and OS (24.2 months vs. 14.5 months vs. 9.3 months, P < 0.001) in ICI monotherapy compared to intermediate or poor LIPI status. No differences in PFS (17.9 vs. 9.9 months vs. 7.6 months, P = 0.355, respectively) and OS (P = 0.346) were observed in patients who received ICIs CC. Moreover, we found that patients who had an improved LIPI status compared with the baseline value had a longer PFS with ICI monotherapy and LIPI intermediate status (8.4 months vs. 2.1 months vs. 1.4 months, P < 0.001). However, in patients treated with ICIs CC, these dynamic changes were not observed (P = 0.444).

Conclusions: Lung immune prognostic index status and dynamic changes in LIPI could be prognostic markers of treatment response to ICI monotherapy, but not to ICIs CC. In particular, good LIPI status was associated with a better clinical outcome compared with intermediate and poor LIPI status in ICI monotherapy treatment.

Keywords: biomarker; chemotherapy; immune checkpoint inhibitor; lung immune prognostic index; non-small cell lung cancer.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Kaplan Meier estimates of progression-free survival (PFS) and overall survival (OS) according to the Lung Immune Prognostic Index (LIPI) groups in patients with ICI monotherapy (A) PFS in the ICI monotherapy group (P = 0.023); (B) OS in the ICI monotherapy group (P < 0.001).
FIGURE 2
FIGURE 2
Kaplan Meier estimates of progression-free survival (PFS) and overall survival (OS) according to the Lung Immune Prognostic Index (LIPI) groups in patients with ICIs combination group (A) PFS in the ICIs combination group (P = 0.355); (B) OS in the ICIs combination group (P = 0.346).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. (2018) 359:1350–5. 10.1126/science.aar4060 - DOI - PMC - PubMed
    1. Park YJ, Kuen DS, Chung Y. Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance. Exp Mol Med. (2018) 50:109. 10.1038/s12276-018-0130-1 - DOI - PMC - PubMed
    1. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csõszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. (2016) 375:1823–33. 10.1056/NEJMoa1606774 - DOI - PubMed
    1. Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicenter randomised controlled trial. Lancet. (2017) 389:255–65. 10.1016/S0140-6736(16)32517-X - DOI - PMC - PubMed
    1. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. (2015) 373:123–35. 10.1056/NEJMoa1504627 - DOI - PMC - PubMed

LinkOut - more resources